JP2002529415A5 - - Google Patents

Download PDF

Info

Publication number
JP2002529415A5
JP2002529415A5 JP2000580627A JP2000580627A JP2002529415A5 JP 2002529415 A5 JP2002529415 A5 JP 2002529415A5 JP 2000580627 A JP2000580627 A JP 2000580627A JP 2000580627 A JP2000580627 A JP 2000580627A JP 2002529415 A5 JP2002529415 A5 JP 2002529415A5
Authority
JP
Japan
Prior art keywords
preparation
oral administration
pharmaceutical
moxifloxacin
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000580627A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002529415A (ja
JP4809978B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1999/008230 external-priority patent/WO2000027398A1/de
Publication of JP2002529415A publication Critical patent/JP2002529415A/ja
Publication of JP2002529415A5 publication Critical patent/JP2002529415A5/ja
Application granted granted Critical
Publication of JP4809978B2 publication Critical patent/JP4809978B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000580627A 1998-11-10 1999-10-29 製薬学的モキシフロキサシン調製物 Expired - Lifetime JP4809978B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19855758 1998-11-10
DE19855758.2 1998-11-10
PCT/EP1999/008230 WO2000027398A1 (de) 1998-11-10 1999-10-29 Pharmazeutische zubereitung von moxifloxacin

Publications (3)

Publication Number Publication Date
JP2002529415A JP2002529415A (ja) 2002-09-10
JP2002529415A5 true JP2002529415A5 (https=) 2006-12-21
JP4809978B2 JP4809978B2 (ja) 2011-11-09

Family

ID=7889824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000580627A Expired - Lifetime JP4809978B2 (ja) 1998-11-10 1999-10-29 製薬学的モキシフロキサシン調製物

Country Status (41)

Country Link
US (1) US6610327B1 (https=)
EP (1) EP1128831B1 (https=)
JP (1) JP4809978B2 (https=)
KR (1) KR100650489B1 (https=)
CN (1) CN1149993C (https=)
AR (1) AR021074A1 (https=)
AT (1) ATE279193T1 (https=)
AU (1) AU745282B2 (https=)
BG (1) BG64974B1 (https=)
BR (2) BR9915208A (https=)
CA (1) CA2349161C (https=)
CO (1) CO5070571A1 (https=)
CU (1) CU23260B7 (https=)
CZ (1) CZ292069B6 (https=)
DE (1) DE59910858D1 (https=)
DK (1) DK1128831T3 (https=)
EE (1) EE04418B1 (https=)
ES (1) ES2229786T3 (https=)
HK (1) HK1042245B (https=)
HN (1) HN1999000183A (https=)
HR (1) HRP20010332B1 (https=)
HU (1) HU229065B1 (https=)
ID (1) ID29089A (https=)
IL (2) IL142642A0 (https=)
MA (1) MA26757A1 (https=)
MY (1) MY121114A (https=)
NO (1) NO319342B1 (https=)
NZ (1) NZ511554A (https=)
PE (1) PE20001304A1 (https=)
PL (1) PL194020B1 (https=)
PT (1) PT1128831E (https=)
RU (1) RU2230555C9 (https=)
SI (1) SI1128831T1 (https=)
SK (1) SK283936B6 (https=)
SV (1) SV1999000194A (https=)
TR (1) TR200101310T2 (https=)
TW (1) TW580388B (https=)
UA (1) UA72483C2 (https=)
UY (1) UY25792A1 (https=)
WO (1) WO2000027398A1 (https=)
ZA (1) ZA200103141B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika
EP1663226A1 (en) * 2003-09-03 2006-06-07 Ranbaxy Laboratories Limited Pharmaceutical compositions of moxifloxacin and processes for their preparation
CN1330306C (zh) * 2004-08-11 2007-08-08 深圳市天一时科技开发有限公司 莫西沙星明胶胶囊剂及其制备方法
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
CN100363001C (zh) * 2005-09-21 2008-01-23 深圳市天一时科技开发有限公司 一种莫西沙星胶囊剂及其制备方法
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
PT2349220E (pt) * 2008-10-09 2012-10-11 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Utilização de solventes orgânicos na granulação húmida de moxifloxacina
WO2010066385A1 (de) 2008-12-08 2010-06-17 Ratiopharm Gmbh Kompaktiertes moxifloxacin
TR200907227A2 (tr) * 2009-09-18 2011-04-21 Bi̇lgi̇ç Mahmut Çözünürlüğü yüksek stabil mikronize granüller.
CN101890169B (zh) * 2009-11-16 2013-09-11 江苏亚邦强生药业有限公司 莫西沙星口服制剂及其制备方法
WO2011086577A2 (en) * 2010-01-12 2011-07-21 Msn Laboratories Limited Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts
CN102247313A (zh) * 2010-06-11 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服缓释固体制剂
CN102247314A (zh) * 2011-01-12 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服固体制剂
EP2510929A1 (en) * 2011-04-11 2012-10-17 Innocoll Technologies Limited Methods for treating bacterial infection
MX2011004759A (es) 2011-05-04 2012-11-21 Senosiain S A De C V Lab Nuevas formas solidas de antibioticos.
RU2466718C1 (ru) * 2011-10-14 2012-11-20 Закрытое акционерное общество "Брынцалов-А" Фармацевтический препарат моксифлоксацина
US9358261B2 (en) 2011-10-25 2016-06-07 U.S. Phytotherapy, Inc. Additional artemisinin and berberine compositions and methods of making
WO2013063271A1 (en) * 2011-10-25 2013-05-02 U.S. Phytotherapy, Inc. Artemisinin and berberine compositions and methods of making
EP2770985A4 (en) 2011-10-25 2015-01-21 U S Phytotherapy Inc ARTEMISININE AND BERBERINE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
US9675582B2 (en) 2011-10-25 2017-06-13 U.S. Phytotherapy, Inc. Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the Zika virus
BR112014012994A2 (pt) * 2011-11-30 2017-06-13 Toyama Chemical Co Ltd tablete contendo hidrato de metanossulfonato do ácido 1-ciclopropil-8-(difluorometóxi)-7-[(1r)-1-metil-2,3-diidro-1h-isoindol-5-il]-4-oxo-1, 4-diidroquinolina-3-carboxílico
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
CN102525982A (zh) * 2012-02-21 2012-07-04 天津市汉康医药生物技术有限公司 一种稳定的盐酸莫西沙星药物组合物
CN102600093B (zh) * 2012-04-11 2013-06-05 南京优科生物医药有限公司 一种莫西沙星片剂及其制备方法
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN103768063B (zh) * 2012-10-19 2016-04-20 深圳信立泰药业股份有限公司 一种盐酸莫西沙星药物组合物及其制备方法
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
WO2015093669A1 (ko) * 2013-12-20 2015-06-25 씨제이헬스케어 주식회사 목시플록사신 수성 제형 및 이의 제조방법
RU2558932C1 (ru) * 2014-05-22 2015-08-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция моксифлоксацина и способ ее приготовления

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601566A1 (de) * 1986-01-21 1987-07-23 Bayer Ag Pharmazeutische zubereitungen von ciprofloxacin
US5286754A (en) 1986-01-21 1994-02-15 Bayer Aktiengesellschaft Pharmaceutical formulations of ciprofloxacin
WO1989003681A1 (en) * 1987-10-19 1989-05-05 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma
JPH01175936A (ja) * 1987-12-28 1989-07-12 Kyorin Pharmaceut Co Ltd 6.8−ジフルオロ−1−(2−フルオロエチル)−1,4−ジヒドロ−7−(4−メチル−1−ピペラジニル)−4−オキソ−3−キノリンカルボン酸を有効成分とする錠剤
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
EP0449445A3 (en) * 1990-03-27 1993-08-25 Pfizer Inc. Preparation of beta-ketoesters useful in preparing quinolone antibiotics
TW209865B (https=) * 1992-01-10 1993-07-21 Bayer Ag
DE19546249A1 (de) * 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
PA8466701A1 (es) * 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino

Similar Documents

Publication Publication Date Title
JP2002529415A5 (https=)
CA2349161A1 (en) Pharmaceutical moxifloxacin preparation
RU2001116096A (ru) Фармацевтический препарат моксифлоксацина
CA2307018A1 (en) Osmotic medicament releasing system
NO20012222D0 (no) Farmasöytisk formulering innbefattende omeprazol
CA2360248A1 (en) Combinations of formoterol and a tiotropium salt
WO2001039745A3 (en) Aerosol composition comprising formoterol
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
CA2363990A1 (en) Use of glycyrrhizin in the treatment of mastitis
EP1246622A4 (en) NEW SUBSTITUTED DOSE FORMS OF BENZIMIDAZOLENES AND METHOD FOR THE USE THEREOF
AU2001230892A1 (en) Orally administered pharmaceutical formulations of benzimidazole derivatives andthe method of preparing the same
CA2337046A1 (en) Sustained release pharmaceutical preparation
CA2427815A1 (en) Controlled release hydrocodone formulations
JP2003506416A5 (https=)
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
CA2378424A1 (en) Moxifloxacin formulation containing common salt
GEP20053501B (en) Core Tablet for Controlled Release of Gliclazide after Oral Administration
JP2001503780A5 (https=)
DE60020501D1 (de) Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe
IL159217A0 (en) An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine
PL343936A1 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
ZA200308221B (en) Pharmaceutical compositions for oral and topical administration.
HUP0304085A2 (en) The citrate salt of 5,8,14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
HUP0200363A3 (en) Lhrh antagonist decapeptides, pharmaceutical compositions comprising thereof and processes for their preparation
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine